Insmed (INSM) falls 18% premarket after reporting the results of a Phase 3 trial for Arikace....
Insmed (INSM) falls 18% premarket after reporting the results of a Phase 3 trial for Arikace. Although the treatment achieved the primary non-inferiority endpoint, it appears Arikace did not show as well as tobramycin inhalation solution in terms of FEV1 (see presentation, slide 3).
From other sites
at CNBC.com (Jun 18, 2014)
at CNBC.com (Mar 26, 2014)
at CNBC.com (Oct 27, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs